Tian-Yu Cai
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Tian-Yu Cai has a total of 111 co-authors. Here are the top co-authors by number of shared publications:
- Bo Yang
School of Information Science and Engineering, Hunan Institute of Science and Technology, Yueyang, Hunan, China
7 shared publications Ji Cao
7 shared publications- Jian-Shu Lou
School of Pharmacy, Hangzhou Normal University, Hangzhou, Zhejiang 311121, China
7 shared publications - Ling Ding
College of Intelligence and Computing, Tianjin University, Tianjin, China
7 shared publications - Qiaojun He
Center for Drug Safety Evaluation and Research, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China
7 shared publications - Xiaowen Liu
Deming Department of Medicine, School of Medicine, Tulane University, 1441 Canal Street, New Orleans, LA 70112, USA
7 shared publications
Latest Publications
- Open Access
- 6 July 2026
- Published by Springer Nature in Leukemia
- Vol. 40 (9) , 1951-1960
Decreased TXNRD1 is associated with resistance to tagraxofusp in blastic plasmacytoid dendritic cell neoplasms, as seen in phase II
Tagraxofusp is a CD123-targeted therapy comprised of a recombinant human interleukin-3 (IL-3) fused to a truncated diphtheria toxin payload. It is the first approved treatment specifically for patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN). To identify biomarkers of response, bone marrow samples from 12 BPDCN patients who were treated with tagraxofusp in the pivotal phase II trial (NCT02113982) were profiled longitudinally using a gene panel and single-cell RNA sequencing. Residual tumor cells following tagraxofusp expressed lower levels of TXNRD1 that would reduce the efficacy of tagraxofusp. In support of this, enzymatic inhibition of TXNRD1 resulted in higher viability of CAL-1 BPDCN cells following tagraxofusp. Responders had either wild-type or missense TET2 mutations, while transient and non-responders had at least one truncating TET2 mutation. Examples of these mutations within the catalytic domain of TET2 were constructed and transduced into cells. Missense and truncating mutants displayed reduced sensitivities to hypomethylating agents and prolonged S-phase stasis. These results suggest that the levels of TXNRD1 interact with intrinsic TET2 truncating mutations within the bone marrow to modulate patient response to tagraxofusp.
- 6 July 2026
- Published by Springer Nature in Leukemia
- Vol. 40 (9) , 1951-1960
Open AccessDecreased TXNRD1 is associated with resistance to tagraxofusp in blastic plasmacytoid dendritic cell neoplasms, as seen in phase II
Tagraxofusp is a CD123-targeted therapy comprised of a recombinant human interleukin-3 (IL-3) fused to a truncated diphtheria toxin payload. It is the first approved treatment specifically for patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN). To identify biomarkers of response, bone marrow samples from 12 BPDCN patients who were treated with tagraxofusp in the pivotal phase II trial (NCT02113982) were profiled longitudinally using a gene panel and single-cell RNA sequencing. Residual tumor cells following tagraxofusp expressed lower levels of TXNRD1 that would reduce the efficacy of tagraxofusp. In support of this, enzymatic inhibition of TXNRD1 resulted in higher viability of CAL-1 BPDCN cells following tagraxofusp. Responders had either wild-type or missense TET2 mutations, while transient and non-responders had at least one truncating TET2 mutation. Examples of these mutations within the catalytic domain of TET2 were constructed and transduced into cells. Missense and truncating mutants displayed reduced sensitivities to hypomethylating agents and prolonged S-phase stasis. These results suggest that the levels of TXNRD1 interact with intrinsic TET2 truncating mutations within the bone marrow to modulate patient response to tagraxofusp.
- Top Cited Papers
- 19 September 2024
- Published by Springer Nature in Nature Cancer
- Vol. 5 (10) , 1515-1533
Glutaminase inhibition in combination with azacytidine in myelodysplastic syndromes: a phase 1b/2 clinical trial and correlative analyses
Malignancies are reliant on glutamine as an energy source and a facilitator of aberrant DNA methylation. We demonstrate preclinical synergy of telaglenastat (CB-839), a selective glutaminase inhibitor, combined with azacytidine (AZA), followed by a single-arm, open-label, phase 1b/2 study in persons with advanced myelodysplastic syndrome (MDS). The dual primary endpoints evaluated clinical activity, safety and tolerability; secondary endpoints evaluated pharmacokinetics, pharmacodynamics, overall survival, event-free survival and duration of response. The dose-escalation study included six participants and the dose-expansion study included 24 participants. Therapy was well tolerated and led to an objective response rate of 70% with (marrow) complete remission in 53% of participants and a median overall survival of 11.6 months, with evidence of myeloid differentiation in responders determined by single-cell RNA sequencing. Glutamine transporter solute carrier family 38 member 1 in MDS stem cells was associated with clinical responses and predictive of worse prognosis in a large MDS cohort. These data demonstrate the safety and efficacy of CB-839 and AZA as a combined metabolic and epigenetic approach in MDS. ClinicalTrials.gov identifier: NCT03047993.
- 19 September 2024
- Published by Springer Nature in Nature Cancer
- Vol. 5 (10) , 1515-1533
Top Cited PapersGlutaminase inhibition in combination with azacytidine in myelodysplastic syndromes: a phase 1b/2 clinical trial and correlative analyses
Malignancies are reliant on glutamine as an energy source and a facilitator of aberrant DNA methylation. We demonstrate preclinical synergy of telaglenastat (CB-839), a selective glutaminase inhibitor, combined with azacytidine (AZA), followed by a single-arm, open-label, phase 1b/2 study in persons with advanced myelodysplastic syndrome (MDS). The dual primary endpoints evaluated clinical activity, safety and tolerability; secondary endpoints evaluated pharmacokinetics, pharmacodynamics, overall survival, event-free survival and duration of response. The dose-escalation study included six participants and the dose-expansion study included 24 participants. Therapy was well tolerated and led to an objective response rate of 70% with (marrow) complete remission in 53% of participants and a median overall survival of 11.6 months, with evidence of myeloid differentiation in responders determined by single-cell RNA sequencing. Glutamine transporter solute carrier family 38 member 1 in MDS stem cells was associated with clinical responses and predictive of worse prognosis in a large MDS cohort. These data demonstrate the safety and efficacy of CB-839 and AZA as a combined metabolic and epigenetic approach in MDS. ClinicalTrials.gov identifier: NCT03047993.
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 - 2 from Tirapazamine Sensitizes Hepatocellular Carcinoma Cells to Topoisomerase I Inhibitors via Cooperative Modulation of Hypoxia-Inducible Factor-1α
PDF file - 135K, Supplementary Table S1. CI Values of SN-38 at Concentrations Applied in Combination with Tirapazamine in Different Liver Cell Lines; Supplementary Table S2. In Vivo Efficacy of CPT-11 in Combination with Tirapazamine; and supplementary figure legends.
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 - 2 from Tirapazamine Sensitizes Hepatocellular Carcinoma Cells to Topoisomerase I Inhibitors via Cooperative Modulation of Hypoxia-Inducible Factor-1α
PDF file - 135K, Supplementary Table S1. CI Values of SN-38 at Concentrations Applied in Combination with Tirapazamine in Different Liver Cell Lines; Supplementary Table S2. In Vivo Efficacy of CPT-11 in Combination with Tirapazamine; and supplementary figure legends.
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 2 from Tirapazamine Sensitizes Hepatocellular Carcinoma Cells to Topoisomerase I Inhibitors via Cooperative Modulation of Hypoxia-Inducible Factor-1α
PDF file - 166K, Figure S2. TPZ enhanced the cytotoxicity elicited by several topoisomerase I inhibitors in Bel-7402 cells under hypoxia.
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 2 from Tirapazamine Sensitizes Hepatocellular Carcinoma Cells to Topoisomerase I Inhibitors via Cooperative Modulation of Hypoxia-Inducible Factor-1α
PDF file - 166K, Figure S2. TPZ enhanced the cytotoxicity elicited by several topoisomerase I inhibitors in Bel-7402 cells under hypoxia.
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 5 from Tirapazamine Sensitizes Hepatocellular Carcinoma Cells to Topoisomerase I Inhibitors via Cooperative Modulation of Hypoxia-Inducible Factor-1α
PDF file - 59K, Figure S5. Overexpression of HIF-1alpha is associated with resistance to topoisomerase I inhibitors in HCC cells.
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 5 from Tirapazamine Sensitizes Hepatocellular Carcinoma Cells to Topoisomerase I Inhibitors via Cooperative Modulation of Hypoxia-Inducible Factor-1α
PDF file - 59K, Figure S5. Overexpression of HIF-1alpha is associated with resistance to topoisomerase I inhibitors in HCC cells.
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 6 from Tirapazamine Sensitizes Hepatocellular Carcinoma Cells to Topoisomerase I Inhibitors via Cooperative Modulation of Hypoxia-Inducible Factor-1α
PDF file - 89K, Figure S6. Overexpression of HIF-1α could weaken the synergistic effect of SN-38 and TPZ.
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 6 from Tirapazamine Sensitizes Hepatocellular Carcinoma Cells to Topoisomerase I Inhibitors via Cooperative Modulation of Hypoxia-Inducible Factor-1α
PDF file - 89K, Figure S6. Overexpression of HIF-1α could weaken the synergistic effect of SN-38 and TPZ.
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 3 from Tirapazamine Sensitizes Hepatocellular Carcinoma Cells to Topoisomerase I Inhibitors via Cooperative Modulation of Hypoxia-Inducible Factor-1α
PDF file - 293K, Figure S3. TPZ enhanced the cytotoxicity elicited by topoisomerase I inhibitors under hypoxia.
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 3 from Tirapazamine Sensitizes Hepatocellular Carcinoma Cells to Topoisomerase I Inhibitors via Cooperative Modulation of Hypoxia-Inducible Factor-1α
PDF file - 293K, Figure S3. TPZ enhanced the cytotoxicity elicited by topoisomerase I inhibitors under hypoxia.
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from Tirapazamine Sensitizes Hepatocellular Carcinoma Cells to Topoisomerase I Inhibitors via Cooperative Modulation of Hypoxia-Inducible Factor-1α
PDF file - 159K, Figure S1. Depletion of HIF-1alpha could reverse hypoxia-induced resistance to topoisomerase I inhibitors.
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from Tirapazamine Sensitizes Hepatocellular Carcinoma Cells to Topoisomerase I Inhibitors via Cooperative Modulation of Hypoxia-Inducible Factor-1α
PDF file - 159K, Figure S1. Depletion of HIF-1alpha could reverse hypoxia-induced resistance to topoisomerase I inhibitors.
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 4 from Tirapazamine Sensitizes Hepatocellular Carcinoma Cells to Topoisomerase I Inhibitors via Cooperative Modulation of Hypoxia-Inducible Factor-1α
PDF file - 131K, Figure S4. TPZ and SN-38 decrease the rate of HIF-1alpha protein synthesis.
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 4 from Tirapazamine Sensitizes Hepatocellular Carcinoma Cells to Topoisomerase I Inhibitors via Cooperative Modulation of Hypoxia-Inducible Factor-1α
PDF file - 131K, Figure S4. TPZ and SN-38 decrease the rate of HIF-1alpha protein synthesis.